Ardelyx (ARDX) Competitors $4.82 +0.22 (+4.78%) Closing price 04:00 PM EasternExtended Trading$4.86 +0.04 (+0.81%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. ELAN, PCVX, RYTM, PTCT, ZLAB, ACLX, RARE, RNA, AKRO, and MRUSShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Elanco Animal Health (ELAN), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), Akero Therapeutics (AKRO), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Zai Lab Arcellx Ultragenyx Pharmaceutical Avidity Biosciences Akero Therapeutics Merus Ardelyx (NASDAQ:ARDX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Do insiders and institutionals hold more shares of ARDX or ELAN? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 5.9% of Ardelyx shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer ARDX or ELAN? In the previous week, Elanco Animal Health had 6 more articles in the media than Ardelyx. MarketBeat recorded 14 mentions for Elanco Animal Health and 8 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.89 beat Elanco Animal Health's score of 0.50 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, ARDX or ELAN? Ardelyx has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Which has better earnings & valuation, ARDX or ELAN? Ardelyx has higher earnings, but lower revenue than Elanco Animal Health. Ardelyx is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.62M3.41-$39.14M-$0.16-29.84Elanco Animal Health$4.44B0.93-$1.23B$0.6712.41 Is ARDX or ELAN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Ardelyx's net margin of -11.73%. Elanco Animal Health's return on equity of 6.78% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-11.73% -24.87% -10.51% Elanco Animal Health 4.60%6.78%3.03% Do analysts prefer ARDX or ELAN? Ardelyx currently has a consensus target price of $10.61, suggesting a potential upside of 122.22%. Elanco Animal Health has a consensus target price of $14.67, suggesting a potential upside of 76.39%. Given Ardelyx's stronger consensus rating and higher possible upside, research analysts plainly believe Ardelyx is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the MarketBeat Community believe in ARDX or ELAN? Ardelyx received 395 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 54.62% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53767.46% Underperform Votes25932.54% Elanco Animal HealthOutperform Votes14254.62% Underperform Votes11845.38% SummaryArdelyx beats Elanco Animal Health on 10 of the 19 factors compared between the two stocks. Remove Ads Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10B$6.27B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-28.756.6921.6917.68Price / Sales3.29222.71373.9692.89Price / CashN/A65.6738.1534.64Price / Book6.305.776.363.94Net Income-$39.14M$142.01M$3.20B$247.45M7 Day Performance8.24%5.79%3.96%3.17%1 Month Performance-15.13%-15.47%-10.34%-8.53%1 Year Performance-29.77%-10.99%10.38%0.32% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.2459 of 5 stars$4.82+4.8%$10.61+120.1%-31.4%$1.15B$333.62M-30.1390Analyst RevisionNews CoverageELANElanco Animal Health4.3479 of 5 stars$8.69+0.8%$14.67+68.8%-40.3%$4.31B$4.44B21.739,800Analyst ForecastPCVXVaxcyte3.2719 of 5 stars$32.04+2.7%$136.50+326.0%-53.2%$4.13BN/A-6.97160Positive NewsRYTMRhythm Pharmaceuticals3.8274 of 5 stars$60.14+1.0%$74.92+24.6%+59.2%$3.80B$130.13M-13.89140Analyst RevisionPTCTPTC Therapeutics3.8944 of 5 stars$45.08+4.9%$63.77+41.5%+83.5%$3.56B$806.78M-7.591,410Upcoming EarningsShort Interest ↑Positive NewsZLABZai Lab2.8645 of 5 stars$31.52+6.7%$47.37+50.3%+100.6%$3.46B$398.99M-11.381,950Gap UpHigh Trading VolumeACLXArcellx2.013 of 5 stars$60.30+1.9%$110.67+83.5%+9.9%$3.31B$107.94M-84.9380Positive NewsRAREUltragenyx Pharmaceutical4.5074 of 5 stars$34.92+2.3%$92.79+165.7%-17.3%$3.28B$560.23M-5.511,310Analyst RevisionPositive NewsRNAAvidity Biosciences1.966 of 5 stars$26.91+5.2%$66.69+147.8%+7.7%$3.23B$10.90M-9.34190AKROAkero Therapeutics4.2114 of 5 stars$37.60+5.4%$76.29+102.9%+71.8%$2.99BN/A-10.0330Insider TradeMRUSMerus2.9564 of 5 stars$42.43+1.1%$85.31+101.1%+4.0%$2.93B$36.13M-10.7437Positive News Remove Ads Related Companies and Tools Related Companies ELAN Competitors PCVX Competitors RYTM Competitors PTCT Competitors ZLAB Competitors ACLX Competitors RARE Competitors RNA Competitors AKRO Competitors MRUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.